Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: An ASAS initiative

Annals of the Rheumatic Diseases

Volumn 75, Issue 6, 2016, Pages 991-996

  Gossec, Laure ^a,b   Portier, Agnès ^a,c,d   Landewé, Robert ^e   Etcheto, Adrien ^c,d   Navarro Compán, Victoria ^f,g   Kroon, Féline ^f   Van Der Heijde, Désirée ^f   Dougados, Maxime ^c,d  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Institut Cochin   (France)

^e Zuyderland Medical Centre   (Netherlands)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTHRALGIA; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CONSENSUS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE EXACERBATION; EXERCISE; HUMAN; MEDICAL EXPERT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; SPONDYLARTHRITIS; SYSTEMATIC REVIEW; VALIDATION STUDY; ADULT; AGED; COMPLICATION; DISEASE COURSE; FEMALE; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PATHOLOGY; PROCEDURES; QUESTIONNAIRE; SECOND CERVICAL VERTEBRA; SEVERITY OF ILLNESS INDEX; STANDARDS; SYMPTOM ASSESSMENT; YOUNG ADULT;

ADULT; AGED; AXIS, CERVICAL VERTEBRA; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; REFERENCE VALUES; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; SURVEYS AND QUESTIONNAIRES; SYMPTOM ASSESSMENT; YOUNG ADULT;

EID: 84958087907     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208593     Document Type: Article

References (27)

1. Mengshoel AM. Living with a fluctuating illness of ankylosing spondylitis: a qualitative study. Arthritis Rheum 2008;59:1439-44.
2. Trijau S, Avouac J, Escalas C, et al. Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage 2010;18:1012-18.
3. Sieper J, Lenaerts J, Wollenhaupt J, et al. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis 2014;73:108-13.
4. Cantini F, Niccoli L, Cassarà E, et al. Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study. Biol Targets Ther 2012;6:201-6.
5. Bautista-Molano W, Navarro-Compán V, Landewé RBM, et al. How well are the ASAS/OMERACT Core Outcome Sets for Ankylosing Spondylitis implemented in randomized clinical trials? A systematic literature review. Clin Rheumatol 2014;33:1313-22.
6. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(Suppl 2):ii1-44.
7. Hermann KGA, Baraliakos X, van der Heijde DMFM, et al. Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group. Ann Rheum Dis 2012;71:1278-88.
8. Bartlett SJ, Bykerk VP, Cooksey R, et al. Feasibility and domain validation of rheumatoid arthritis (RA) flare core domain set: report of the OMERACT 2014 RA flare group plenary. J Rheumatol 2015;42:2185-9.
9. Bartlett SJ, Hewlett S, Bingham CO, et al. Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. Ann Rheum Dis 2012;71:1855-60.
10. Cooksey R, Brophy S, Gravenor MB, et al. Frequency and characteristics of disease flares in ankylosing spondylitis. Rheumatol Oxf Engl 2010;49: 929-32.
11. Brophy S, Calin A. Definition of disease flare in ankylosing spondylitis: the patients' perspective. J Rheumatol 2002;29:954-8.
12. Stone MA, Pomeroy E, Keat A, et al. Assessment of the impact of flares in ankylosing spondylitis disease activity using the Flare Illustration. Rheumatol Oxf Engl 2008;47:1213-18.
13. Godfrin-Valnet M, Puyraveau M, Prati C, et al. Flare in spondyloarthritis: Thresholds of disease activity variations. Jt Bone Spine Rev Rhum 2015;82:192-5.
14. Veloski J, Tai S, Evans AS, et al. Clinical vignette-based surveys: a tool for assessing physician practice variation. Am J Med Qual 2005;20:151-7.
15. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
16. Lukas C, Landewé R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18-24.
17. Machado P, Navarro-Compán V, Landewé R, et al. Calculating the ankylosing spondylitis disease activity score if the conventional c-reactive protein level is below the limit of detection or if high-sensitivity c-reactive protein is used: an analysis in the DESIR cohort. Arthritis Rheumatol 2015;67:408-13.
18. Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53.
19. Banks J, Hollinghurst S, Bigwood L, et al. Preferences for cancer investigation: a vignette-based study of primary-care attendees. Lancet Oncol 2014;15:232-40.
20. Das J, Kwan A, Daniels B, et al. Use of standardised patients to assess quality of tuberculosis care: a pilot, cross-sectional study. Lancet Infect Dis 2015;15: 1305-13.
21. Dougados M, Simon P, Braun J, et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011;70:249-51.
22. Hewlett S, Sanderson T, May J, et al. 'I'm hurting, I want to kill myself': rheumatoid arthritis flare is more than a high joint count - an international patient perspective on flare where medical help is sought. Rheumatol 2012;51:69-76.
23. Pavy S, Brophy S, Calin A. Establishment of the minimum clinically important difference for the bath ankylosing spondylitis indices: a prospective study. J Rheumatol 2005;32:80-5.
24. Tubach F, Wells GA, Ravaud P, et al. Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: methodological issues. J Rheumatol 2005;32:2025-9.
25. Curtis JR, Yang S, Chen L, et al. Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis. Arthritis Care Res (Hoboken) 2015;67:1345-53.
26. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
27. Wariaghli G, Allali F, Idrissi Z, et al. Evaluation and stability of the Patient Acceptable Symptom State (PASS) over time in patients with ankylosing spondylitis. Clin Exp Rheumatol 2012;30:106-9.